Recombinant Salmonella typhimurium Beta-lactamase CTX-M-2 (bla)

What is CTX-M-2 beta-lactamase and what is its significance in antimicrobial resistance?

CTX-M-2 is an extended-spectrum beta-lactamase (ESBL) belonging to the CTX-M family of enzymes that hydrolyze extended-spectrum cephalosporins, particularly cefotaxime (hence the "CTX" designation). CTX-M-2 has been widely distributed in South America since at least 1989, before its appearance in Europe, making it one of the earliest documented CTX-M variants .

The significance of CTX-M-2 in antimicrobial resistance is substantial as it represents part of what researchers call the "CTX-M pandemic," characterized by worldwide dissemination of these resistance determinants . Enteropathogens such as Vibrio cholerae and Salmonella species were among the first microorganisms identified carrying the bla CTX-M-2 gene . The enzyme confers resistance to clinically important beta-lactam antibiotics while typically showing less activity against ceftazidime compared to cefotaxime.

In Brazil, CTX-M-2-producing Salmonella enterica isolates have been recovered from poultry-rearing environments and foodstuffs, indicating transmission pathways between animal production environments and the food chain . This demonstrates the enzyme's ability to spread across different ecological niches, posing significant public health concerns beyond clinical settings.

How is CTX-M-2 detected in Salmonella strains?

Detection of CTX-M-2 in Salmonella strains requires a combination of phenotypic and genotypic methods for comprehensive characterization:

Phenotypic Methods:

• Kirby-Bauer susceptibility testing to establish resistance patterns (CTX-M-2 producers typically show resistance to cefotaxime but variable resistance to ceftazidime)

• Broth microdilution for determining Minimum Inhibitory Concentrations (MICs), revealing characteristic patterns like high cefotaxime MICs (>64 μg/ml)

• Isoelectric focusing (IEF) analysis, which for CTX-M-2 demonstrates two characteristic bands with pIs of 7.95 and 8.0

• Beta-lactamase inhibition tests using clavulanic acid to demonstrate ESBL activity (significant MIC reduction when combined with beta-lactams)

Genotypic Methods:

• PCR amplification and sequencing of the bla CTX-M-2 gene using specific primers

• Pulsed-field gel electrophoresis (PFGE) for strain typing (isolates may group into specific PFGE clusters like clusters A and B for Schwarzengrund and Agona serotypes)

• Plasmid analysis to identify the plasmid carrying bla CTX-M-2 (approximately 40 kb IncP plasmid in Salmonella enterica)

• Transformation experiments to confirm gene transferability (transformants demonstrate increased cefotaxime MICs)

In the research described, transformants obtained with 38.5% of ESBL-producing strains exhibited a 5-fold increase in cefotaxime MICs, confirming the transfer of resistance . These complementary approaches provide reliable identification and characterization of CTX-M-2-producing Salmonella strains.

What are the genetic characteristics of the bla CTX-M-2 gene?

The bla CTX-M-2 gene possesses several distinctive genetic characteristics that contribute to its dissemination and resistance profile:

Genetic Location and Mobilization:

• In Salmonella enterica isolates, bla CTX-M-2 is typically carried on an IncP plasmid of approximately 40 kb

• The gene is highly transferable, with successful transformation into recipient strains like E. coli TOP10 demonstrating its mobility

• The plasmid location facilitates horizontal gene transfer between different bacterial species and genera

Sequence and Structure:

• bla CTX-M-2 belongs to one of the major phylogenetic groups of CTX-M beta-lactamases

• The wild-type sequence confers high-level resistance to cefotaxime but limited activity against ceftazidime

• The gene can undergo mutations that significantly alter substrate specificity, particularly the Pro-to-Ser mutation at position 167 (Ambler numbering system) that enhances ceftazidime hydrolysis

Evolutionary Context:

• CTX-M beta-lactamases originated from chromosomal genes of environmental bacteria, particularly Kluyvera species

• bla CTX-M-2 was among the earliest CTX-M genes identified, dating back to at least 1989 in South America

• The gene has spread to multiple Salmonella serotypes, including emerging clinically relevant serotypes like Schwarzengrund and Agona

The genetic environment surrounding bla CTX-M-2 plays a crucial role in its mobilization and expression. These genes are typically associated with insertion sequences and transposons that facilitate their movement between different genetic platforms, contributing to their successful dissemination across bacterial populations.

What is the antibiotic resistance profile of CTX-M-2-producing Salmonella?

CTX-M-2-producing Salmonella exhibits a distinctive antibiotic resistance profile that reflects the enzyme's substrate preferences and associated resistance mechanisms:

Resistant to:

• Beta-lactams: Ampicillin (MIC >64 μg/ml)

• Extended-spectrum cephalosporins: Cefotaxime (MIC >64 μg/ml), Cefpodoxime (MIC >128 μg/ml), Ceftriaxone (MIC >64 μg/ml)

• Other beta-lactams: Piperacillin (MIC >128 μg/ml), Cefazolin (MIC >32 μg/ml)

Variable resistance to:

• Aztreonam (MIC 32 μg/ml)

• Cefepime (MIC >32 μg/ml)

Susceptible to:

• Kanamycin, Gentamicin, Amikacin

• Chloramphenicol

• Amoxicillin-clavulanic acid (MIC 16 μg/ml)

• Cefoxitin (MIC 4 μg/ml)

• Carbapenems: Imipenem (MIC 0.5 μg/ml), Meropenem (MIC ≤0.25 μg/ml)

A defining characteristic of CTX-M-2 is its preferential hydrolysis of cefotaxime over ceftazidime (MIC 4 μg/ml for wild-type), though experimental studies have shown that mutant variants can develop enhanced ceftazidime resistance . The enzyme's activity is inhibited by beta-lactamase inhibitors like clavulanic acid, as demonstrated by the significantly reduced MICs when antibiotics are combined with clavulanic acid .

Table 1: Representative MICs for wild-type CTX-M-2 and mutant variants with P167S mutation. AMP: Ampicillin, AMC: Amoxicillin-clavulanic acid, CAZ: Ceftazidime, CTX: Cefotaxime, FEP: Cefepime, IPM: Imipenem, MEM: Meropenem

How did CTX-M beta-lactamases evolve and spread globally?

The evolution and global spread of CTX-M beta-lactamases, including CTX-M-2, represent a paradigm in the evolution of antimicrobial resistance mechanisms:

Origin:

• CTX-M beta-lactamases originated from chromosomal genes of environmental bacteria, particularly Kluyvera species

• CTX-M-2 has been widely distributed in South America since at least 1989, before appearing in Europe

• Enteropathogens such as Vibrio cholerae and Salmonella species were among the first microorganisms found to carry the bla CTX-M-2 gene

Historical Context:

• Early CTX-M enzymes included MEN-1 (later identified as identical to CTX-M-1) isolated from an Italian patient

• Toho-1 and Toho-2 enzymes (later renamed CTX-M-44 and CTX-M-45) were identified in Japan in the 1990s

• These early discoveries established the foundation for understanding the CTX-M family of beta-lactamases

Spread Mechanisms:

• Incorporation of bla CTX-M genes into highly mobilizable genetic platforms (plasmids and transposons)

• Successful bacterial clones serving as effective hosts for these genetic elements

• Co-resistance to other antibiotics (particularly aminoglycosides and fluoroquinolones) leading to co-selection processes

Factors Influencing Dissemination:

• Antibiotic consumption patterns in different geographic areas

• Different risk factors in various patient populations and ecological niches

• The explosive global spread has been termed the "CTX-M pandemic"

• CTX-M-15 and CTX-M-14 have become the most prevalent variants worldwide, surpassing earlier variants like CTX-M-2

The remarkable success of CTX-M beta-lactamases is attributed to their efficient hydrolysis of clinically important cephalosporins and their exceptional ability to disseminate through mobile genetic elements in diverse bacterial hosts across multiple ecological compartments, including humans, animals, and the environment.

What experimental approaches can predict the evolution of ceftazidime resistance in CTX-M-2?

Predicting the evolution of ceftazidime resistance in CTX-M-2 requires sophisticated experimental approaches that simulate evolutionary processes in laboratory settings. Based on published research, a comprehensive methodology involves:

In vitro Evolution Method:

• Gene Mutagenesis:

  • Mutagenize the bla CTX-M-2 gene using error-prone PCR with Mutazyme DNA polymerase

  • Digest mutagenized genes with restriction enzymes (BspHI and SacI)

  • Clone into an appropriate vector (pACSE3)

  • Transform into E. coli (DH5αE) with selection for an appropriate marker (tetracycline resistance)

• Selection for Ceftazidime Resistance:

  • Expose the transformants to increasing concentrations of ceftazidime

  • Isolate colonies showing enhanced resistance

• Phenotypic Characterization:

  • Determine MICs by broth microdilution according to NCCLS guidelines

  • Compare MICs for various beta-lactams between wild-type and mutant enzymes

  • Use appropriate quality control organisms (E. coli ATCC 25922, S. aureus ATCC 29213, P. aeruginosa ATCC 27853)

• Enzyme Characterization:

  • Prepare cell lysates using freeze-thaw procedures

  • Perform isoelectric focusing to visualize beta-lactamases

  • Stain IEF gels with nitrocefin to determine pI values

  • Compare with reference beta-lactamases (TEM-1, SHV-5, TEM-3, MIR-1)

• Genetic Analysis:

  • Sequence the mutant bla CTX-M-2 alleles

  • Identify mutations and correlate with phenotypic changes

  • Retransform purified plasmids to confirm the phenotype is plasmid-mediated

Research implementing this approach revealed that a single Pro-to-Ser mutation at position 167 (Ambler numbering system) was critical for conferring ceftazidime resistance, with all 10 mutant bla CTX-M-2 alleles analyzed containing this mutation . This enhanced ceftazidime hydrolysis came with a significant trade-off: reduced cefepime hydrolysis, with MICs decreasing from >32 μg/ml to 1-2 μg/ml .

This evolutionary trade-off between ceftazidime and cefepime resistance may explain why naturally occurring ceftazidime-resistant variants of CTX-M-2 have not been frequently detected in clinical settings, despite the theoretical evolutionary potential .

How do mutations in the bla CTX-M-2 gene affect the enzyme's substrate specificity?

Mutations in the bla CTX-M-2 gene can profoundly alter the substrate specificity of the enzyme, creating variants with different hydrolytic profiles against various beta-lactam antibiotics:

Key Mutation - P167S (Pro-to-Ser at position 167):

• Present in all experimentally evolved CTX-M-2 mutants selected for ceftazidime resistance

• Dramatically increases ceftazidime hydrolysis (MICs increase from 4 μg/ml to 32-128 μg/ml)

• Significantly decreases cefepime hydrolysis (MICs decrease from >32 μg/ml to 1-2 μg/ml)

• Changes the enzyme's isoelectric point (from pIs of 7.95 and 8.0 to 7.90 and 7.95 for one mutant)

Additional Mutations Identified in Experimental Evolution:
From the DNA mutation table in the experimental study, several other mutations were observed in different clones:

Table 2: Mutations identified in CTX-M-2 mutants selected for ceftazidime resistance

Notably, the P167S mutation occurs naturally in bla CTX-M-19 (a member of the bla CTX-M-9 group), which also demonstrates enhanced ceftazidime hydrolysis (MIC = 128 μg/ml) but decreased cefepime hydrolysis (MIC = 4 μg/ml) compared to its ancestor bla CTX-M-18 (cefepime MIC = 16 μg/ml) .

This substrate specificity shift represents an evolutionary trade-off, suggesting that the enzyme's active site cannot be optimally configured for both ceftazidime and cefepime hydrolysis simultaneously. This molecular constraint may influence the evolutionary trajectories of CTX-M enzymes under different selective pressures in clinical settings.

What molecular mechanisms underlie the spread of bla CTX-M-2 genes across different bacterial species?

The dissemination of bla CTX-M-2 genes across different bacterial species involves several sophisticated molecular mechanisms that facilitate horizontal gene transfer:

Plasmid-Mediated Transfer:

• The bla CTX-M-2 gene is associated with an IncP plasmid of approximately 40 kb in Salmonella enterica isolates

• These plasmids can be successfully transformed into recipient strains (e.g., E. coli TOP10), demonstrating their transferability

• The transformation efficiency in experimental settings was 38.5% of ESBL-producing strains, indicating significant transfer capability

• IncP plasmids have a broad host range, facilitating transfer across diverse bacterial genera

Mobile Genetic Elements:

• CTX-M genes are incorporated into highly mobilizable genetic platforms, including plasmids and transposons

• These mobile elements facilitate the movement of resistance genes between different genetic contexts

• The incorporation of bla CTX-M-2 into such elements has enabled its mobilization from the original chromosomal source in Kluyvera species

Bacterial Clone Success:

• The presence of bla CTX-M-2 within successful bacterial clones enhances its dissemination

• In Salmonella, isolates belonging to serotypes Schwarzengrund and Agona (PFGE clusters A and B, respectively) were found to produce CTX-M-2

• These serotypes are described as "emerging clinically relevant Salmonella serotypes," suggesting fitness advantages that contribute to dispersal

Co-resistance Mechanisms:

• CTX-M-producing organisms often exhibit co-resistance to other antibiotic classes, particularly aminoglycosides and fluoroquinolones

• This co-resistance facilitates co-selection processes, where the use of one antibiotic class selects for resistance to multiple antibiotics

• The maintenance of resistance genes in the absence of direct selection pressure contributes to persistence of these genes in bacterial populations

Ecological Transmission Routes:

• CTX-M-2-producing Salmonella has been isolated from poultry-rearing environments and foodstuffs in Brazil

• These ecological niches serve as reservoirs for resistance genes and contribute to their dissemination

• The spread between animal production, food chain, and human clinical settings represents important transmission pathways

Understanding these molecular mechanisms provides critical insights for developing strategies to limit the spread of antimicrobial resistance and for predicting the emergence of new resistance patterns in clinical settings.

How do environmental factors influence the expression and activity of CTX-M-2 in Salmonella?

Environmental factors can significantly impact the expression and activity of CTX-M-2 beta-lactamase in Salmonella through multiple mechanisms:

Antibiotic Selection Pressure:

• The use of extended-spectrum cephalosporins, particularly cefotaxime, selects for CTX-M-2-producing organisms

• Different antibiotic consumption patterns in various geographic areas influence the prevalence of specific CTX-M variants

• In poultry production, antibiotic usage practices create selective pressures that favor the emergence and persistence of resistant strains

Host Environment and Ecological Niches:

• CTX-M-2-producing Salmonella has been isolated from poultry-rearing environments in southern Brazil (states of Santa Catarina and Paraná)

• The conditions in these environments (antibiotic usage, animal density, hygiene practices) affect the selection and spread of resistant strains

• The identification of CTX-M-2 in different Salmonella serotypes (Schwarzengrund and Agona) suggests adaptation to specific ecological niches

Genetic Context and Expression Regulation:

• The expression of bla CTX-M-2 is influenced by its genetic context on the ~40 kb IncP plasmid

• Promoter sequences and regulatory elements on the plasmid could respond to environmental signals

• The stable maintenance of the plasmid in the absence of selection pressure depends on environmental conditions

Enzymatic Activity Parameters:

• Beta-lactamase activity can be affected by environmental conditions such as temperature and pH

• The isoelectric focusing results show that CTX-M-2 has pIs of 7.95 and 8.0, suggesting optimal activity near neutral to slightly alkaline pH

• Host physiological conditions (mammalian body temperature, intestinal pH) may influence enzyme kinetics and stability

Co-selection by Multiple Antimicrobials:

• The co-resistance to multiple antibiotic classes mentioned in the literature enables selection by various antibiotics

• Use of non-beta-lactam antibiotics can co-select for CTX-M-2-producing organisms even without beta-lactam pressure

• This phenomenon contributes to the maintenance of resistance genes in diverse environments with varied antibiotic usage patterns

Methodological approaches to study these environmental influences include gene expression analysis under various conditions, enzyme kinetic studies at different temperatures and pH values, investigation of regulatory elements controlling bla CTX-M-2 expression, and ecological studies of CTX-M-2 prevalence across environments with varying antibiotic use patterns.

What are the current challenges in detecting and characterizing CTX-M-2 variants in clinical and environmental samples?

Researchers face several significant challenges when detecting and characterizing CTX-M-2 variants in clinical and environmental samples:

Phenotypic Detection Challenges:

• Variability in resistance profiles among CTX-M-2 variants due to mutations like P167S that alter substrate specificity

• Potential for false-negative results in standard ESBL detection tests, particularly when variants show unexpected resistance patterns

• Difficulty in distinguishing CTX-M-2 from other ESBLs based solely on resistance phenotypes

• Varying levels of enzyme expression affecting the reliability of phenotypic tests

Molecular Detection Challenges:

• Genetic diversity within the CTX-M-2 group requiring broad-spectrum primers or multiple PCR assays

• The potential for new mutations that may affect primer binding sites in evolved variants

• Challenges in designing specific primers that distinguish CTX-M-2 from closely related variants

• Differentiating between the presence of the gene and its expression in heterogeneous samples

Environmental Sample Processing:

• Low bacterial concentrations in environmental samples requiring enrichment steps

• Complex sample matrices from poultry farms and food products that may inhibit PCR or other detection methods

• Presence of viable but non-culturable bacteria carrying bla CTX-M-2

• Distinguishing between dead and viable bacteria containing resistance genes

Characterization Complications:

• Labor-intensive nature of full sequencing for comprehensive characterization of variants

• Difficulty in predicting phenotypic properties from genotypic data, as seen with the P167S mutation's effects

• Challenges in determining the complete genetic context of bla CTX-M-2 (plasmid type, surrounding genetic elements)

• Limited understanding of the fitness costs associated with different mutations in various environments

Emerging Research Needs:

• Development of rapid and reliable methods for detecting and characterizing CTX-M-2 variants

• Understanding the evolutionary constraints exemplified by the trade-off between ceftazidime and cefepime resistance

• Elucidating the ecological niches and transmission routes between poultry environments and human infections

• Investigating the impact of CTX-M-2 variants on treatment outcomes and infection control strategies

Addressing these challenges requires integrated approaches combining phenotypic methods (like MIC determination and IEF), molecular techniques (multiplex PCR, whole genome sequencing), and advanced analytical tools to comprehensively characterize CTX-M-2 variants and understand their evolutionary dynamics in various ecological niches.